证券代码：688278 证券简称：特宝生物 公告编号：2025-029 厦门特宝生物工程股份有限公司 第九届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 鉴于公司 2024 年年度权益分派方案已于 2025 年 5 月 9 日实施完毕，以方案 实施前的公司总股本 406,800,000 股为基数，每股派发现金红利 0.62 元（含税）， 不送红股，不进行资本公积转增股本。根据《上市公司股权激励管理办法》、公 司《2024 年限制性股票激励计划（草案）》等相关规定及 2024 年第一次临时股 东大会的授权，董事会对 2024 年限制性股票激励计划首次及预留授予价格进行 相应调整，由 39.80 元/股调整为 39.18 元/股。除上述调整内容外，本次预留授予 的内容与公司 2024 年第一次临时股东大会审议通过的《2024 年限制性股票激励 计划（草案）》一致。 董事长孙黎先生、董事赖力平女士为本次限制性股票激励对象，与董事杨英 女士、蓝柏林先生、孙邃先生均为关联董事，对 ...

Core Viewpoint - The AI Fund Huashang Innovation Medical Mixed A (017418) reported a profit of 5.2361 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.1359 yuan, and a net value growth rate of 17.87% during the reporting period [2] Group 1: Fund Performance - As of September 3, 2025, the fund's unit net value was 1.121 yuan, with a recent three-month net value growth rate of 25.16%, ranking 65 out of 138 in its category [5] - The fund's six-month net value growth rate was 27.59%, ranking 103 out of 138, while the one-year growth rate was 50.85%, ranking 85 out of 136 [5] - The fund's maximum drawdown since inception was 29.03%, with the largest quarterly drawdown occurring in Q1 2024 at 16.93% [26] Group 2: Fund Holdings and Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 16.88 times, significantly lower than the category average of 120.96 times [9] - The weighted average price-to-book (P/B) ratio was about 1.09 times, compared to the category average of 4.07 times, and the weighted average price-to-sales (P/S) ratio was approximately 0.99 times, against a category average of 6.52 times [9] - The fund's stock holdings showed a weighted revenue growth rate of 0.04% and a weighted net profit growth rate of 0.19% for the first half of 2025 [14] Group 3: Fund Management and Strategy - The fund manager, Peng Xinyang, oversees three funds, all of which have achieved positive returns over the past year, with the highest being Huashang Industrial Upgrade Mixed Fund at 66.97% [2] - The fund management anticipates that the global collaboration trend in innovative drugs will continue, benefiting the CXO industry from sustained R&D investments [2] - The report highlights the potential for innovative medical devices and the commercialization of medical AI to become new leading themes in the pharmaceutical industry [2] Group 4: Fund Structure and Investor Composition - As of June 30, 2025, the fund had a total of 369 holders, with a total of 37.1517 million shares held [33] - Institutional investors held 53.83% of the shares, while individual investors accounted for 46.17% [33] - The fund's average stock position since inception was 79.64%, with a peak of 90.68% in the first half of 2024 [29]

Group 1 - The A-share innovative drug sector experienced a strong rebound, with the Biopharmaceutical ETF (159839) rising by 4.17% and a trading volume exceeding 44 million yuan [1] - The Biopharmaceutical ETF (159839) has seen a net inflow of over 15 million yuan for two consecutive days [1] - Several innovative drug companies reported significant stock price increases, with notable gains including 9.99% for Zhaoyan New Drug and 7.53% for Changchun High-tech [2] Group 2 - The pharmaceutical industry is experiencing structural differentiation, with a 0.7% decline in revenue and a 1.5% increase in net profit for listed companies in the first half of 2025 [3] - Leading innovative drug companies are achieving profitability, driven by strong sales of key products such as Zebutinib and Furmetinib [3] - The innovative drug sector is expected to benefit from improved policies and a downward trend in global central bank interest rates, which may enhance long-term valuations [4] Group 3 - The CXO industry is entering a recovery phase, with a resurgence in overseas demand expected by the end of 2023, leading to a recovery in domestic head companies' orders in 2024 [5] - The domestic innovative drug assets are progressing into late clinical stages, with increasing validation of clinical data and a clear trend towards internationalization [5]

Core Viewpoint - Changchun High-tech is facing significant challenges with declining revenues and profits, indicating a struggle to maintain its market position amid increasing competition and pricing pressures in the pharmaceutical industry [1][6]. Financial Performance - In the first half of 2025, Changchun High-tech reported revenue of 6.603 billion yuan, a slight decrease of 0.54% year-on-year, while net profit attributable to shareholders fell sharply by 42.85% to 983 million yuan [1]. - For the full year of 2024, the company expects revenue to be 13.466 billion yuan, down 7.55% year-on-year, and net profit to drop by 43.01% to 2.583 billion yuan, marking the first annual revenue decline since 2004 [1]. - The first quarter of 2025 saw a further decline in net profit by 44.95%, with no signs of stabilization in performance [1]. Key Business Segments - Jinsai Pharmaceutical, a major profit source for Changchun High-tech, achieved revenue of 5.469 billion yuan in the first half of 2025, up 6.17% year-on-year, but net profit plummeted by 37.35% to 1.108 billion yuan, highlighting a significant disparity between revenue growth and profit decline [2]. - The core products of Jinsai Pharmaceutical, particularly growth hormone products, are facing challenges due to price pressures from collective procurement policies initiated in 2023, which have significantly impacted profit margins [2]. Cost Structure - Sales expenses for Changchun High-tech reached 2.386 billion yuan in the first half of 2025, an increase of 23.43% year-on-year, while management expenses rose by 31.26% to 724 million yuan, further straining profitability amid stagnant revenue [3]. - Research and development expenses amounted to 1.335 billion yuan, a 17.32% increase year-on-year, representing over 20% of revenue, with the approval of the IL-1β monoclonal antibody "Jinbeixin" marking a significant milestone in the company's biopharmaceutical innovation efforts [3]. Market Competition - The approval of Teva Biopharmaceutical's long-acting growth hormone product "Yipeisheng" in May 2025 has ended Jinsai Pharmaceutical's long-standing monopoly in the growth hormone market, leading to intensified competition [4]. - Other competitors, including international pharmaceutical giant Novo Nordisk, are also entering the market with competitive products, indicating a shift towards a more competitive landscape in the growth hormone sector [4]. Secondary Growth Drivers - The company's secondary growth driver, the shingles vaccine, has also underperformed, with revenue from its subsidiary Baike Bio falling by 53.93% to 285 million yuan in the first half of 2025, and a 71.54% decline expected in 2024 [4][5]. - The overall market for vaccines has been adversely affected by decreased public willingness to receive vaccinations post-COVID-19, compounding the challenges faced by Baike Bio [5]. Conclusion - The decline in net profits and the challenges faced by Changchun High-tech underscore the vulnerabilities of companies heavily reliant on single product lines amid regulatory and competitive pressures [6].

Investment Rating - The report maintains a strong buy rating for the pharmaceutical sector, indicating a bullish outlook for the industry [3]. Core Insights - The pharmaceutical sector is expected to experience a broad rally, driven by innovative drugs leading the charge. The sector index showed a notable upward trend in the first half of 2025, particularly in April, with a valuation premium of 275.19%, significantly above historical averages [4][18]. - Public funds are increasingly favoring pharmaceutical stocks, particularly in innovative drugs and medical devices, supported by stable growth in basic medical insurance funds [4][22]. Section Summaries 1. Market Performance - The pharmaceutical sector has shown a strong upward trend since Q3 2024, outperforming the broader market indices. The sector index rose by 24.51% from the beginning of 2025 to August 29, 2025, surpassing the Shanghai and Shenzhen 300 index by 11.07 percentage points [11][12]. - Medical services and chemical raw materials have performed particularly well, with medical services up by 80.24% and chemical raw materials up by 53.67% as of August 28, 2025 [17]. 2. Industry Overview - The pharmaceutical manufacturing industry has shown resilience, with stable revenue growth and a healthy operating environment for basic medical insurance funds. The overall revenue of the pharmaceutical manufacturing industry has experienced fluctuations but is on a recovery path [31][35]. - The innovative drug business development (BD) has seen explosive growth, with China becoming a hotspot for multinational corporations (MNCs) seeking partnerships. The total transaction amount for BD in 2024 reached a record high of $640.8 billion, with significant contributions from overseas transactions [36][38]. 3. Subsector Analysis - Innovative drugs are leading the growth, with 21 A-share innovative drug companies reporting a revenue of 28.69 billion yuan in the first half of 2025, a year-on-year increase of 42%. The net profit loss has narrowed significantly, indicating a positive trend in profitability [56]. - The medical device sector is also expected to see a turning point in the second half of 2025, with a 62.75% year-on-year growth in the overall bidding market for medical devices in the first half of 2025, exceeding 80 billion yuan [52].

Core Viewpoint - Changchun High-tech's stock surged to a six-month high despite disappointing half-year results, driven by optimistic management forecasts regarding innovative drug revenues and potential business development opportunities [1][2]. Group 1: Financial Performance - Changchun High-tech reported a revenue of 6.603 billion yuan, a slight decrease of 0.54% year-on-year, and a net profit of 983 million yuan, down 42.85% year-on-year [1]. - Its subsidiary, Jinsai Pharmaceutical, achieved a revenue of 5.469 billion yuan, an increase of 6.17% year-on-year, but net profit dropped significantly by 37.35% [2]. Group 2: Product Development and Market Position - The company anticipates that revenues from innovative drugs and overseas licensing will exceed 1 billion yuan this year and 1.5 billion yuan next year, with other revenues surpassing traditional growth hormone business by 2027 [1]. - The recently approved drug, Fuxin Qibai monoclonal antibody, is expected to generate peak sales of 5 billion yuan, with a current market price of 8,988 yuan per unit [1][6]. - Jinsai Pharmaceutical is facing increased competition in the long-acting growth hormone market, particularly from Teva Pharmaceutical's newly launched product priced at 1,798 yuan per unit [4][5]. Group 3: Future Outlook and Strategic Plans - The company plans to initiate a Hong Kong IPO in 2026 and aims to add 10-15 new INDs annually from 2025 to 2030, targeting overseas licensing revenues of 5-8 billion yuan by 2030 [1][9]. - Jinsai Pharmaceutical is also preparing for the market entry of three new products, including the promising Fuxin Qibai monoclonal antibody, which is expected to generate 1 billion yuan in sales this year and 6-10 billion yuan next year [6][7].

Group 1 - The core transaction of Tebo Bio occurred on August 29, with a volume of 41,900 shares and a transaction amount of 3.4811 million yuan, at a price of 83.08 yuan per share [2] - In the last three months, Tebo Bio has had a total of 12 block trades, with a cumulative transaction amount of 141 million yuan [3] - The closing price of Tebo Bio on the same day was 83.08 yuan, reflecting an increase of 0.42%, with a daily turnover rate of 0.53% and a total transaction amount of 180 million yuan [3] Group 2 - The latest margin financing balance for Tebo Bio is 1.418 billion yuan, which has decreased by 6.9228 million yuan over the past five days, representing a decline of 0.49% [4] - Three institutions have provided ratings for Tebo Bio in the last five days, with the highest target price set by Dongfang Securities at 103.36 yuan as of August 29 [4]

Group 1 - On August 29, 2025, TeBao Bio conducted a block trade of 41,900 shares, with a transaction amount of 3.4811 million yuan, accounting for 1.89% of the total transaction volume for the day [1][2] - The transaction price was 83.08 yuan, which remained stable compared to the market closing price of 83.08 yuan [1][2]

Investment Rating - The report maintains a "Buy" rating for the company [6][3] Core Views - The company is experiencing rapid growth with a rich pipeline of products, particularly focusing on the clinical cure of chronic hepatitis B [9][3] - The core product "Peginterferon" has gained recognition for its effectiveness in improving clinical cure rates and significantly reducing the risk of liver cancer, driving both revenue and profit growth [9][3] - The company has a strong financial outlook, with projected earnings per share of 2.72, 3.66, and 4.58 yuan for 2025, 2026, and 2027 respectively, and a target price of 103.36 yuan based on a 38x PE valuation for 2025 [3][6] Financial Summary - Revenue is projected to grow from 2,100 million yuan in 2023 to 6,232 million yuan in 2027, with a compound annual growth rate (CAGR) of 27.7% [5] - Operating profit is expected to increase from 681 million yuan in 2023 to 2,134 million yuan in 2027, reflecting a CAGR of 24.5% [5] - Net profit attributable to the parent company is forecasted to rise from 555 million yuan in 2023 to 1,862 million yuan in 2027, with a CAGR of 25.1% [5] - The gross margin is expected to remain stable around 93%, while the net margin is projected to peak at 30.5% in 2025 and then slightly decline to 29.9% by 2027 [5] - The return on equity (ROE) is anticipated to be around 37% in the coming years, indicating strong profitability [5] Product Development and Pipeline - The company is increasing its R&D investment, with a research expense ratio of 11.6% in the first half of 2025, up 2.0 percentage points year-on-year [9] - The long-acting growth hormone has been approved for market release, enhancing the product matrix [9] - Multiple projects are in various stages of clinical research, including treatments for chronic hepatitis B and metabolic disorders [9]

Investment Rating - The report maintains a "Buy" rating for the company [6][3]. Core Views - The company is experiencing rapid growth, with a focus on enhancing the clinical cure rate for hepatitis B through its core product, "Peginterferon" [9]. - The company has a robust pipeline with ongoing clinical trials and new product approvals, including a long-acting growth hormone [9]. - Financial forecasts indicate significant revenue and profit growth, with projected earnings per share of 2.72, 3.66, and 4.58 yuan for 2025, 2026, and 2027 respectively [3][5]. Financial Summary - Revenue is expected to grow from 2,100 million yuan in 2023 to 6,232 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 27.7% [5]. - Net profit attributable to the parent company is projected to increase from 555 million yuan in 2023 to 1,862 million yuan in 2027, with a CAGR of about 25.1% [5]. - The company's gross margin is expected to remain stable around 93%, while the net margin is projected to improve from 26.4% in 2023 to 29.9% in 2027 [5]. Valuation Metrics - The target price for the company is set at 103.36 yuan, based on a price-to-earnings (PE) ratio of 38 times for 2025 [3][6]. - The company's current market capitalization is approximately 33,655 million yuan [6].